DK1097922T3 - 5-Thia-omega-substituerede phenyl-prostaglandin E derivater, fremgangsmåde til fremstilling deraf samt lægemidler indeholdende forbindelsen som aktiv bestanddel - Google Patents
5-Thia-omega-substituerede phenyl-prostaglandin E derivater, fremgangsmåde til fremstilling deraf samt lægemidler indeholdende forbindelsen som aktiv bestanddelInfo
- Publication number
- DK1097922T3 DK1097922T3 DK99929831T DK99929831T DK1097922T3 DK 1097922 T3 DK1097922 T3 DK 1097922T3 DK 99929831 T DK99929831 T DK 99929831T DK 99929831 T DK99929831 T DK 99929831T DK 1097922 T3 DK1097922 T3 DK 1097922T3
- Authority
- DK
- Denmark
- Prior art keywords
- thia
- prostaglandin
- omega
- substituted phenyl
- disease
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 230000009885 systemic effect Effects 0.000 abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010050685 Cytokine storm Diseases 0.000 abstract 1
- 208000013558 Developmental Bone disease Diseases 0.000 abstract 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000011200 Kawasaki disease Diseases 0.000 abstract 1
- 208000004987 Macrophage activation syndrome Diseases 0.000 abstract 1
- 208000034486 Multi-organ failure Diseases 0.000 abstract 1
- 208000010718 Multiple Organ Failure Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 206010072610 Skeletal dysplasia Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 231100000354 acute hepatitis Toxicity 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 206010052015 cytokine release syndrome Diseases 0.000 abstract 1
- 238000000502 dialysis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 abstract 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP20075298 | 1998-07-15 | ||
PCT/JP1999/003798 WO2000003980A1 (fr) | 1998-07-15 | 1999-07-14 | DERIVES DE PHENYL-POSTAGLANDINE E 5-THIA-φ-SUBSTITUES, PROCEDE DE PRODUCTION DESDITS DERIVES ET MEDICAMENTS CONTENANT LESDITS DERIVES EN TANT QUE PRINCIPE ACTIF |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1097922T3 true DK1097922T3 (da) | 2005-05-30 |
Family
ID=16429595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99929831T DK1097922T3 (da) | 1998-07-15 | 1999-07-14 | 5-Thia-omega-substituerede phenyl-prostaglandin E derivater, fremgangsmåde til fremstilling deraf samt lægemidler indeholdende forbindelsen som aktiv bestanddel |
Country Status (21)
Country | Link |
---|---|
US (1) | US6462081B1 (no) |
EP (1) | EP1097922B1 (no) |
JP (1) | JP3174563B2 (no) |
KR (1) | KR100598660B1 (no) |
CN (1) | CN1173945C (no) |
AT (1) | ATE291013T1 (no) |
AU (1) | AU763668B2 (no) |
BR (1) | BR9912813B1 (no) |
CA (1) | CA2336952C (no) |
DE (1) | DE69924258T2 (no) |
DK (1) | DK1097922T3 (no) |
ES (1) | ES2239448T3 (no) |
HU (1) | HUP0204170A3 (no) |
NO (1) | NO327781B1 (no) |
NZ (1) | NZ509293A (no) |
PT (1) | PT1097922E (no) |
RU (1) | RU2220135C2 (no) |
TR (1) | TR200100623T2 (no) |
TW (1) | TWI249520B (no) |
WO (1) | WO2000003980A1 (no) |
ZA (1) | ZA200100295B (no) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4834224B2 (ja) | 1999-03-05 | 2011-12-14 | デューク ユニバーシティ | C16不飽和fp−選択的プロスタグランジン類縁体 |
CA2303060A1 (en) * | 1999-04-14 | 2000-10-14 | United States Gear Corporation | Towed vehicle brake controller |
WO2001024800A1 (fr) * | 1999-10-07 | 2001-04-12 | Ono Pharmaceutical Co., Ltd. | Remedes contre le dysfonctionnement de l'erection |
TWI247606B (en) * | 1999-11-24 | 2006-01-21 | Ono Pharmaceutical Co | Treating agent for osteopenic diseases |
AU2227401A (en) * | 2000-01-05 | 2001-07-16 | Ono Pharmaceutical Co. Ltd. | 5-thia-omega-(substituted phenyl)-prostaglandin e alcohols, process for preparing the alcohols and pharmaceutical preparations containing the same as the activeingredient |
DE60120007T2 (de) | 2000-01-31 | 2006-11-16 | Pfizer Products Inc., Groton | Verwendung von Aktivatoren des Prostaglandinrezeptores 4 zur Behandlung von akuter oder chronischer Niereninsuffizienz |
US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US6586462B2 (en) * | 2000-10-20 | 2003-07-01 | Allergan, Inc. | ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists |
GB0030541D0 (en) * | 2000-12-14 | 2001-01-31 | Glaxo Group Ltd | Medical uses |
GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
AU2002328338C1 (en) | 2001-07-16 | 2009-01-08 | Ono Pharmaceutical Co., Ltd | 2 pyrrolidone derivatives as prostanoid agonists |
CN1893977B (zh) * | 2001-07-23 | 2012-12-05 | 小野药品工业株式会社 | 以ep4激动剂为活性成分的治疗与骨质损失有关的疾病的药物 |
MXPA04000757A (es) * | 2001-07-23 | 2004-07-08 | Ono Pharmaceutical Co | Remedios para enfermedades con perdida de masa de hueso que tienen agonistas ep4 como ingrediente activo. |
US7491748B2 (en) | 2001-08-09 | 2009-02-17 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
JP2003078830A (ja) * | 2001-09-03 | 2003-03-14 | Sony Corp | デジタル放送受信装置および通信情報伝送方法 |
EP1467738A1 (en) * | 2001-10-08 | 2004-10-20 | Medical Research Council | Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus |
ATE371454T1 (de) * | 2001-10-31 | 2007-09-15 | Medical Res Council | Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie |
WO2003037373A1 (en) * | 2001-10-31 | 2003-05-08 | Medical Research Council | Use of an ep2 or ep4 receptor antagonist and/or a cox-1 inhibitor for treating cervical cancer |
US20040258730A1 (en) * | 2001-11-12 | 2004-12-23 | Yasuhiko Tabata | Persistent filmy preparation for topical administration containing prostglandin derivative |
MXPA04009036A (es) * | 2002-03-18 | 2005-01-25 | Pfizer Prod Inc | Uso de agonistas del receptor ep4 selectivos para el tratamiento de la insuficiencia hepatica, perdida de permeabilidad del ductus arterioso, glaucoma o hipertension ocular. |
GB0208785D0 (en) * | 2002-04-17 | 2002-05-29 | Medical Res Council | Treatment methtods |
WO2003103772A1 (en) * | 2002-06-06 | 2003-12-18 | Merck Frosst Canada & Co. | 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma |
MXPA04004371A (es) * | 2002-08-09 | 2004-08-13 | Taisho Pharmaceutical Co Ltd | Agente antipruritico. |
US7737182B2 (en) | 2002-08-09 | 2010-06-15 | Taisho Pharmaceutical Co., Ltd. | Pharmaceuticals for xerosis |
ES2393321T3 (es) * | 2002-10-10 | 2012-12-20 | Ono Pharmaceutical Co., Ltd. | Promotores de la producción de factores de reparación endógenos |
WO2004043471A1 (ja) * | 2002-11-13 | 2004-05-27 | Taisho Pharmaceutical Co., Ltd. | 鎮痒剤 |
CN1764635A (zh) * | 2003-02-07 | 2006-04-26 | 小野药品工业株式会社 | 羧酸化合物 |
US7855226B2 (en) | 2003-02-11 | 2010-12-21 | Allergan, Inc. | Treatment of inflammatory bowel disease |
JP4662926B2 (ja) | 2003-03-03 | 2011-03-30 | メルク セローノ ソシエテ アノニム | プロスタグランジン作動薬としてのγ−ラクタム誘導体 |
WO2005012232A2 (en) | 2003-07-18 | 2005-02-10 | Applied Research Systems Ars Holding N.V. | Hydrazide derivatives as prostaglandin receptors modulators |
BRPI0509993A (pt) * | 2004-04-20 | 2007-10-16 | Pfizer Prod Inc | combinações compreendendo ligandos de alfa-2-delta |
EP1782830A4 (en) * | 2004-08-10 | 2009-07-29 | Ono Pharmaceutical Co | PREVENTION AND / OR REMEDY FOR LOWER URINARY TRACT DISEASES CONTAINING AN EP4 AGONIST |
JPWO2006016695A1 (ja) * | 2004-08-10 | 2008-05-01 | 小野薬品工業株式会社 | Ep4アゴニストを含有してなる高カリウム血症の予防および/または治療剤 |
US20080132543A1 (en) * | 2004-10-26 | 2008-06-05 | Wha Bin Im | Therapeutic and Delivery Methods of Prostaglandin Ep4, Agonists |
WO2006075690A1 (ja) * | 2005-01-14 | 2006-07-20 | Ono Pharmaceutical Co., Ltd. | 安定な医薬組成物 |
WO2006118173A1 (ja) | 2005-04-28 | 2006-11-09 | Ono Pharmaceutical Co., Ltd. | 経皮吸収製剤 |
GB0524103D0 (en) | 2005-11-26 | 2006-01-04 | Medical Res Council | Healing |
US7511168B2 (en) | 2006-01-18 | 2009-03-31 | Shih-Yi Wei | Processes and intermediates for the preparations of prostaglandins |
UY30121A1 (es) | 2006-02-03 | 2007-08-31 | Glaxo Group Ltd | Nuevos compuestos |
EP2085088A4 (en) | 2006-10-26 | 2012-08-29 | Ono Pharmaceutical Co | ADHESIVE PREPARATION |
CA2672631A1 (en) | 2006-12-15 | 2008-06-19 | Glaxo Group Limited | Benzamide derivatives as ep4 receptor agonists |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
KR20100016299A (ko) * | 2007-05-08 | 2010-02-12 | 고쿠리츠다이가쿠호진 하마마츠이카다이가쿠 | Ep4 아고니스트를 함유하여 이루어지는 세포 상해성 t 세포의 활성화제 |
GB0721611D0 (en) | 2007-11-02 | 2007-12-12 | Glaxo Group Ltd | Novel compounds |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
CA2739571A1 (en) | 2008-10-29 | 2010-08-26 | Aerie Pharmaceuticals, Inc. | Amino acid salts of prostaglandins |
WO2010077101A2 (ko) | 2008-12-30 | 2010-07-08 | 조선대학교산학협력단 | 신규한 티아졸리딘디온 유도체 및 그의 용도 |
ES2834451T3 (es) | 2009-05-01 | 2021-06-17 | Aerie Pharmaceuticals Inc | Inhibidores de mecanismo doble para el tratamiento de enfermedades |
WO2012016109A2 (en) * | 2010-07-30 | 2012-02-02 | Allergan, Inc. | Compounds and methods for skin repair |
US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US20120142684A1 (en) * | 2010-12-02 | 2012-06-07 | Allergan, Inc. | Compounds and methods for skin repair |
EP2675491A2 (en) | 2011-02-17 | 2013-12-25 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
WO2013105997A2 (en) | 2011-02-23 | 2013-07-18 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
WO2013123270A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
WO2013123272A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
EP2814526B1 (en) | 2012-02-16 | 2016-11-02 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
EP2814527A1 (en) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
EP2846793A1 (en) | 2012-05-09 | 2015-03-18 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease |
KR102151578B1 (ko) | 2012-07-19 | 2020-09-03 | 카이맨 케미칼 컴파니 인코포레이티드 | Ep4-매개의 골 관련 질병 및 질환을 위한 디플루오로락탐 조성물 |
JP6400479B2 (ja) | 2012-10-29 | 2018-10-03 | 株式会社カルディオ | 肺疾患特異的治療剤 |
US9676712B2 (en) | 2013-03-15 | 2017-06-13 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
CN110396085A (zh) | 2013-03-15 | 2019-11-01 | 爱瑞制药公司 | 联合治疗 |
JP2016527006A (ja) | 2013-07-19 | 2016-09-08 | ケイマン ケミカル カンパニー, インコーポレーテッド | 骨成長を促進するための方法、システム、及び組成物 |
WO2015056504A1 (ja) | 2013-10-15 | 2015-04-23 | 小野薬品工業株式会社 | 薬剤溶出性ステントグラフト |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
MX2019002396A (es) | 2016-08-31 | 2019-07-08 | Aerie Pharmaceuticals Inc | Composiciones oftalmicas. |
KR20190135027A (ko) | 2017-03-31 | 2019-12-05 | 에어리 파마슈티컬즈, 인코포레이티드 | 아릴 시클로프로필-아미노-이소퀴놀리닐 아미드 화합물 |
EP3849555A4 (en) | 2018-09-14 | 2022-05-04 | Aerie Pharmaceuticals, Inc. | ARYL CYCLOPROPYL AMINO ISOCHINOLINYL AMIDE COMPOUNDS |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58198466A (ja) | 1982-05-12 | 1983-11-18 | Teijin Ltd | 5−チアプロスタグランジン類およびその製造法 |
JPH072711B2 (ja) | 1986-09-24 | 1995-01-18 | 帝人株式会社 | プロスタグランジンe▲下1▼誘導体の製造法 |
JPH03223244A (ja) * | 1989-02-20 | 1991-10-02 | Ono Pharmaceut Co Ltd | 5―ヘテロ―6―オキソ―pge誘導体、それらの製造方法およびそれらを含有する薬剤 |
EP0386901A1 (en) | 1989-02-20 | 1990-09-12 | Ono Pharmaceutical Co., Ltd. | Novel 5-hetero-6-oxo-PGE derivatives |
JP3579448B2 (ja) * | 1993-12-29 | 2004-10-20 | 大正製薬株式会社 | プロスタグランジン誘導体、その塩およびその使用 |
-
1999
- 1999-07-09 TW TW088111637A patent/TWI249520B/zh not_active IP Right Cessation
- 1999-07-14 WO PCT/JP1999/003798 patent/WO2000003980A1/ja not_active Application Discontinuation
- 1999-07-14 BR BRPI9912813-6A patent/BR9912813B1/pt not_active IP Right Cessation
- 1999-07-14 NZ NZ509293A patent/NZ509293A/en not_active IP Right Cessation
- 1999-07-14 DE DE69924258T patent/DE69924258T2/de not_active Expired - Lifetime
- 1999-07-14 AU AU46518/99A patent/AU763668B2/en not_active Ceased
- 1999-07-14 DK DK99929831T patent/DK1097922T3/da active
- 1999-07-14 US US09/720,675 patent/US6462081B1/en not_active Expired - Fee Related
- 1999-07-14 JP JP2000560089A patent/JP3174563B2/ja not_active Expired - Fee Related
- 1999-07-14 CA CA002336952A patent/CA2336952C/en not_active Expired - Fee Related
- 1999-07-14 RU RU2001101470/04A patent/RU2220135C2/ru not_active IP Right Cessation
- 1999-07-14 AT AT99929831T patent/ATE291013T1/de active
- 1999-07-14 EP EP99929831A patent/EP1097922B1/en not_active Expired - Lifetime
- 1999-07-14 PT PT99929831T patent/PT1097922E/pt unknown
- 1999-07-14 HU HU0204170A patent/HUP0204170A3/hu unknown
- 1999-07-14 KR KR1020017000093A patent/KR100598660B1/ko not_active IP Right Cessation
- 1999-07-14 TR TR2001/00623T patent/TR200100623T2/xx unknown
- 1999-07-14 CN CNB998097039A patent/CN1173945C/zh not_active Expired - Fee Related
- 1999-07-14 ES ES99929831T patent/ES2239448T3/es not_active Expired - Lifetime
-
2001
- 2001-01-10 ZA ZA200100295A patent/ZA200100295B/en unknown
- 2001-01-12 NO NO20010213A patent/NO327781B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ES2239448T3 (es) | 2005-09-16 |
HUP0204170A2 (hu) | 2003-04-28 |
BR9912813B1 (pt) | 2010-11-30 |
CA2336952C (en) | 2009-09-15 |
KR20010053386A (ko) | 2001-06-25 |
EP1097922B1 (en) | 2005-03-16 |
WO2000003980A1 (fr) | 2000-01-27 |
NO20010213L (no) | 2001-03-15 |
AU4651899A (en) | 2000-02-07 |
TR200100623T2 (tr) | 2001-06-21 |
ATE291013T1 (de) | 2005-04-15 |
EP1097922A4 (en) | 2003-02-12 |
DE69924258T2 (de) | 2006-01-26 |
AU763668B2 (en) | 2003-07-31 |
JP3174563B2 (ja) | 2001-06-11 |
NZ509293A (en) | 2003-05-30 |
BR9912813A (pt) | 2001-05-02 |
NO20010213D0 (no) | 2001-01-12 |
ZA200100295B (en) | 2002-07-10 |
KR100598660B1 (ko) | 2006-07-13 |
US6462081B1 (en) | 2002-10-08 |
CN1312796A (zh) | 2001-09-12 |
EP1097922A1 (en) | 2001-05-09 |
CN1173945C (zh) | 2004-11-03 |
DE69924258D1 (de) | 2005-04-21 |
NO327781B1 (no) | 2009-09-21 |
CA2336952A1 (en) | 2000-01-27 |
TWI249520B (en) | 2006-02-21 |
PT1097922E (pt) | 2005-06-30 |
RU2220135C2 (ru) | 2003-12-27 |
HUP0204170A3 (en) | 2005-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1097922T3 (da) | 5-Thia-omega-substituerede phenyl-prostaglandin E derivater, fremgangsmåde til fremstilling deraf samt lægemidler indeholdende forbindelsen som aktiv bestanddel | |
ES2196527T3 (es) | Derivados de 11,15-o-dialquilprostaglandina e, su procedimiento de produccion y medicamentos que incluyen estos como principio activo. | |
EA200101194A1 (ru) | Производные 4,5,6,7-тетрагидроиндазола в качестве противоопухолевых средств | |
ATE73815T1 (de) | Adenosin-derivate und pharmazeutische zusammenstellungen, welche diese als aktiven bestandteil enthalten. | |
ATE323494T1 (de) | Mittel zur verminderung von nebeneffekten | |
NO20050573L (no) | 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler | |
ATE250034T1 (de) | Pyridylverbindungen und diese enthaltende pharmazeutische zubereitungen | |
DE68906609T2 (de) | Dopamin-vorlaeufer. | |
KEATING | Antiviral agents | |
EP1258473A4 (en) | BENZOIC ACID DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL PRODUCT CONTAINING SUCH DERIVATIVES AS ACTIVE INGREDIENT | |
FI891865A0 (fi) | Laekemedel som innehaoller azelastin med kontrollerad frigoering av det verksamma aemnet. | |
IT1271007B (it) | Derivati del 2-ammino-1,2,3,4-tetraidronaftalene attivi sul sistema cardiovascolare | |
ES2215327T3 (es) | Composicion de medicamento inmunomodulador. | |
NO20010454L (no) | Anvendelse av derivater av camptotécin med en redusert gastrointestinal toksisitet | |
Kerr et al. | Highly water-soluble lipophilic prodrugs of the anti-HIV nucleoside analog 2', 3'-dideoxycytidine and its 3'-fluoro derivative | |
KR900012925A (ko) | 인돌 유도체 | |
IL59507A (en) | 5-(10-9)abeo-6-methylergoline derivatives,their preparation and pharmaceutical compositions containing them | |
NO20013408L (no) | Anvendelse av 2-substituerte 1,2-benzisotiazol-derivater og 3- substituerte tetrahydropyridopyrimidinon-derivater for profylakseog terapi av cerebral ischemi | |
KR900017591A (ko) | 2',3'-디데옥시이노신 모노히드레이트, 2',3'- 디데옥시-2',3'-디데히드로티미딘 모노히드레이트 및 2',3'-디데옥시-2'-플루오로이노신 헤미히드레이트의 수용성이 높고 안정한 항비루스 결정체염 | |
ATE169630T1 (de) | Zytostatisch wirksame anthracyclinderivate | |
DK0998464T3 (da) | Polyhydroxyalkylpyrazinderivater, deres fremstilling samt medikamenter indeholdende disse forbindelser | |
ATE307131T1 (de) | Phenanthrolin-7-onderivate und ihre therapeutische verwendung | |
RU99105304A (ru) | Инъекционная форма препарата, проявляющего противоишемическую активность | |
JPS6213325B2 (no) | ||
KR970700672A (ko) | 비페닐메탄 유도체의 칼륨염 및 이를 함유하는 약제(potassium salts of biphenylmethane derivatives and pharmaceuticals containing the same) |